3T Biosciences
PrivateLast Round
Series A
Aug 25, 2022
Total Funding Raised
$52M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
3T Biosciences operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series A round in August 2022.
3T Biosciences is a biotechnology company that develops next-generation T-cell receptor (TCR)-based immunotherapies for solid tumors and immune-mediated diseases using a proprietary target discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
3T Biosciences Comparables
Compare 3T Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ImmunoScape | 86% | |
| BlueSphere Bio | 84% | |
| Repertoire Immune Medicines | 84% |
For institutional investors. Book with your work email.
3T Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 25, 2022 | ||||
| Seed | Oct 5, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
3T Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hayan Health Networks | Seed |
| Westlake Village BioPartners | Series A |
| Thiel Capital | Seed |
| Parker Institute for Cancer Immunotherapy | Seed, Series A |
| Asset Management Ventures | Seed |
| OS Fund | Seed |
| CRV | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Open roles increased to 58, 2.4x the trailing average.
- Jul 26, 2026
Monthly visitors increased 237% MoM, reaching 7.9K.
For institutional investors. Book with your work email.
3T Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about 3T Biosciences's valuation, stock price, and market status.
Is 3T Biosciences a public or private company?
3T Biosciences is a private company.
What is the current stock price of 3T Biosciences?
3T Biosciences is a private company, so its shares have no public market price. Caplight tracks 3T Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is 3T Biosciences worth (valuation)?
Valuation information for 3T Biosciences is not publicly available.
Can I buy 3T Biosciences stock?
3T Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was 3T Biosciences's last funding round?
3T Biosciences's most recent funding round was Series A on August 25, 2022.
Who are the main investors in 3T Biosciences?
Key investors in 3T Biosciences include Westlake Village BioPartners.
Will 3T Biosciences IPO soon?
No public IPO plans have been announced for 3T Biosciences.
How can I track 3T Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in 3T Biosciences's shares on secondary markets.